Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Amylyx Pharmaceuticals, Inc.

NASDAQ: AMLX · Life Sciences · 10 alerts · CIK 1658551

Share price
$27.80Close, Nov 16
Market cap
$3.57B
Shares outstanding
128.56MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Amylyx Pharmaceuticals, Inc. filings on SEC EDGAR ↗

4:00 PM ET Form 4
Insider Selling

Amylyx Pharmaceuticals CFO James M. Frates Sells $1.21M of Stock

James M. Frates, CFO, sold 40,000 shares of Amylyx Pharmaceuticals, Inc. at $29.39 to $30.97 a share (average $30.19) in 4 transactions, worth $1.21M in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 233,625 (-3.0%).

Value
$1.21M
Shares
40,000
Average price
$30.19
Role
CFO
Holding change
-3.0%
Trade date
Nov 9, 2026 to Nov 10, 2026
4:00 PM ET Form 4
Insider Selling

Amylyx Pharmaceuticals Co-CEO Joshua B. Cohen Sells $2.98M of Stock

Joshua B. Cohen, Co-CEO, sold 100,000 shares of Amylyx Pharmaceuticals, Inc. at $29.39 to $30.11 a share (average $29.84) in 2 transactions, worth $2.98M in total on Nov 9, 2026. Shares held after the trade: 3,513,123 (-1.7%).

Value
$2.98M
Shares
100,000
Average price
$29.84
Role
Co-CEO
Holding change
-1.7%
Trade date
Nov 9, 2026
4:00 PM ET Form 4
Insider Selling

Amylyx Pharmaceuticals Co-CEO Justin B. Klee Sells $2.98M of Stock

Justin B. Klee, Co-CEO, sold 100,000 shares of Amylyx Pharmaceuticals, Inc. at $29.39 to $30.11 a share (average $29.84) in 2 transactions, worth $2.98M in total on Nov 9, 2026. Shares held after the trade: 3,513,056 (-1.7%).

Value
$2.98M
Shares
100,000
Average price
$29.84
Role
Co-CEO
Holding change
-1.7%
Trade date
Nov 9, 2026
7:08 AM ET 8-K
Financial Results

Amylyx Pharmaceuticals Financial Results

Amylyx Pharmaceuticals reported third quarter 2026 financial results and provided a business update, highlighting positive Phase 3 LUCIDITY trial results for avexitide in post-bariatric hypoglycemia. The company remains on track to submit a New Drug Application (NDA) by the end of 2026 and recently strengthened its balance sheet with approximately $545 million in net proceeds from a public offering.

“The third quarter was a transformational period for Amylyx, as we reported positive topline results from the Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia, bringing us one step closer to potentially delivering a first ever FDA-approved treatment to people living with PBH.”

Joshua Cohen and Justin Klee, Co-CEOs of Amylyx

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.